Posts by: Jose Marques Lopes, PhD

cystic fibrosis

Treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis (CF) patients could be more effective if done within a crucial two- to three-year period when the bacteria are still susceptible to ... Read more

February 27, 2019March 13, 2019

Low-dose Antibiotics Preserve Airway Bacterial Diversity, but at a Cost, Study Finds

cystic fibrosis

Using lower, or suboptimal, doses of antibiotics to treat lung infections in children and young adults with cystic fibrosis (CF) leads to fewer changes in airway bacterial diversity compared ... Read more

February 4, 2019February 12, 2019

Hypertonic Saline Activates Neurons that Contribute to Airway Surface Liquid Production in CF, Study Suggests

cystic fibrosis

Stimulation of neurons accounts for approximately half of the beneficial production of airway surface liquid (ASL) induced by hypertonic saline (HTS), a therapeutic agent used for cystic fibrosis (CF) treatment, according to ... Read more

January 14, 2019January 21, 2019

Eluforsen Improves CFTR Protein Function in CF Patients with F508del Mutations, Phase 1 Trial Shows

cystic fibrosis, News

An exploratory Phase 1 trial showed that repeated intranasal treatment with the therapy eluforsen improved CFTR protein activity in adults with cystic fibrosis (CF) carrying F508del mutations in both ... Read more

January 11, 2019January 21, 2019

WHO Approves Ensifentrine as Name for Potential Inhaled Treatment Now in Clinical Trials

cystic fibrosis, News

The World Health Organization (WHO) approved ensifentrine as the recommended name to identify the cystic fibrosis (CF) treatment candidate RPL554. Verona Pharma’s ensifentrine is an inhaled inhibitor of the enzymes phosphodiesterase ... Read more

December 17, 2018December 17, 2018

Health Canada Approves Orkambi to Treat Preschoolers with Two F508del Mutations

cystic fibrosis, News

Health Canada has approved Orkambi (ivacaftor/lumacaftor) to treat preschoolers with cystic fibrosis (CF) who carry the F508del mutation in both gene copies of the CFTR gene. Orkambi, developed by Vertex Pharmaceuticals, ... Read more

December 6, 2018December 6, 2018

Inhaled Hypertonic Saline Improves Lung Health in Preschoolers with CF, Study Shows

cystic fibrosis, News

Preschoolers with cystic fibrosis (CF) treated with inhaled hypertonic saline in a clinical trial showed significant improvement in lung function, PARI, the company whose solution and equipment was used in the ... Read more

November 29, 2018November 29, 2018

Triple Combo with VX-659 Improves Lung Function in CF Patients with F508del Mutation, Phase 3 Trials Show

cystic fibrosis, News

Treatment with a triple combination — the new CFTR corrector VX-659, together with tezacaftor and Kalydeco (ivacaftor) — significantly improved lung function and was well-tolerated by cystic fibrosis (CF) patients, ages 12 ... Read more

November 26, 2018November 26, 2018

P. aeruginosa Toxin May Be Reason for Single Strains Found in CF Infections, Study Reports

cystic fibrosis, News

A protein toxin called Tse7 is used by Pseudomonas aeruginosa to kill neighboring bacteria, and may help explain why lung infections in cystic fibrosis patients are often dominated by a ... Read more

November 14, 2018November 14, 2018

Avycaz May Be Effective for Multidrug-resistant P. aeruginosa Infections in CF Patients, Study Suggests

cystic fibrosis, News

Antibacterial Avycaz (ceftazidime-avibactam) showed significant in vitro efficacy against multidrug-resistant Pseudomonas aeruginosa collected from the sputum of cystic fibrosis (CF) patients, according to a recent study. The study, “Multidrug-resistant Pseudomonas aeruginosa from ... Read more

Posts by: Jose Marques Lopes, PhD

Jose Marques Lopes, PhD

Window for More Effective Treatment of CF Lung Infections is 2 to 3 Years, Study Suggests

Low-dose Antibiotics Preserve Airway Bacterial Diversity, but at a Cost, Study Finds

Hypertonic Saline Activates Neurons that Contribute to Airway Surface Liquid Production in CF, Study Suggests

Eluforsen Improves CFTR Protein Function in CF Patients with F508del Mutations, Phase 1 Trial Shows

WHO Approves Ensifentrine as Name for Potential Inhaled Treatment Now in Clinical Trials

Health Canada Approves Orkambi to Treat Preschoolers with Two F508del Mutations

Inhaled Hypertonic Saline Improves Lung Health in Preschoolers with CF, Study Shows

Triple Combo with VX-659 Improves Lung Function in CF Patients with F508del Mutation, Phase 3 Trials Show

P. aeruginosa Toxin May Be Reason for Single Strains Found in CF Infections, Study Reports

Avycaz May Be Effective for Multidrug-resistant P. aeruginosa Infections in CF Patients, Study Suggests

Pin It on Pinterest